IgA Nephropathy (Berger’s Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our IgA Nephropathy (Berger’s Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
IgA nephropathy, also known as Berger’s disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the small blood vessels (glomeruli) within the kidneys. This condition can lead to inflammation, damage, and scarring of the kidneys, affecting their ability to filter waste and excess fluids from the blood. The exact cause of IgA nephropathy is not fully understood, but it is believed to involve an abnormal immune system response, where the body produces IgA antibodies that are not effectively cleared from the bloodstream and deposit in the kidneys. Genetic and environmental factors may also contribute to its development. IgA nephropathy may initially present without noticeable symptoms, but as the disease progresses, individuals may experience blood in the urine (hematuria), which may be visible or detected through urine tests; proteinuria, or the presence of excess protein in the urine; high blood pressure; and swelling in the hands, feet, face, or abdomen due to fluid retention (edema).
The IgA Nephropathy (Berger’s Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for IgA Nephropathy (Berger’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for IgA Nephropathy (Berger’s Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – IgA Nephropathy (Berger's Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 47 molecules, with 47 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of IgA Nephropathy (Berger’s Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed IgA Nephropathy (Berger’s Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of IgA Nephropathy (Berger’s Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AKSO Biopharmaceutical IncAlexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alpine Immune Sciences Inc
Apellis Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
Biohaven Ltd
Calliditas Therapeutics AB
Chinook Therapeutics Inc
Createrna Science and Technology Co Ltd
DiaMedica Therapeutics Inc
Everest Medicines Ltd
F. Hoffmann-La Roche Ltd
Gmax Biopharm LLC
Human Immunology Biosciences Inc
Innovent Biologics Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
KeyMed Biosciences Inc
Kira Pharmaceuticals
Lepton Pharmaceuticals Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Protheragen Inc
RemeGen Co Ltd
Rohto Pharmaceutical Co Ltd
SanReno Therapeutics
Shanghai Alebund Pharmaceuticals Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Meiji Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
The United Laboratories International Holdings Ltd
Transcenta Holding Ltd
Travere Therapeutics Inc
Vera Therapeutics Inc
Viatris Inc
Visterra Inc
Wuxi Biocity Biopharma Co Ltd
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more IgA Nephropathy (Berger's Disease) reports